Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

829.42
+1.880.23%
Pre-market: 829.460.0400+0.00%07:00 EDT
Volume:2.71M
Turnover:2.25B
Market Cap:786.28B
PE:70.83
High:846.01
Open:836.96
Low:818.64
Close:827.54
Loading ...

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss at 40 weeks

Reuters
·
17 Apr

Eli Lilly announces ACHIEVE-1 trial met primary endpoint

TIPRANKS
·
17 Apr

Diabetes Device Maker Dexcom Shares Down 3.1% Premarket After Lilly's Pill Leads to Weight Loss in Late-Stage Trial

THOMSON REUTERS
·
17 Apr

Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell

MT Newswires Live
·
17 Apr

Eli Lilly Shares up 10.3% Premarket After Data Shows Co's Experimental Pill Leads to Weight Loss in Trial

THOMSON REUTERS
·
17 Apr

Lilly pill leads to 7.9% weight loss at 40 weeks in trial

Reuters
·
17 Apr

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

Benzinga
·
17 Apr

Eli Lilly - Expects to Submit Orforglipron for Weight Management, Submission for Treatment of Type 2 Diabetes Anticipated in 2026

THOMSON REUTERS
·
17 Apr

Eli Lilly and Co - Orforglipron Reduces Weight by 16.0 Lbs at Highest Dose

THOMSON REUTERS
·
17 Apr

Eli Lilly and Co - Common Adverse Events for Orforglipron Were Gastrointestinal-Related

THOMSON REUTERS
·
17 Apr

Eli Lilly and Co - Orforglipron Meets Primary Endpoint of a1c Reduction in Phase 3 Trial

THOMSON REUTERS
·
17 Apr

Lilly's Oral Glp-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent With Injectable Glp-1 Medicines in Successful Phase 3 Trial

THOMSON REUTERS
·
17 Apr

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

PR Newswire
·
17 Apr

BUZZ-BMO downgrades Novo Nordisk on faltering lead over Lilly in obesity

Reuters
·
17 Apr

Eli Lilly & Co. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
17 Apr

Novo Nordisk A/S (NVO): A Bull Case Theory

Insider Monkey
·
17 Apr

Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

Zacks
·
16 Apr

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Zacks
·
16 Apr

European pharma companies issue demands to stay in EU ahead of expected US tariffs

Reuters
·
16 Apr

Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth?

Insider Monkey
·
16 Apr